title: [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
abstract: BackgroundBasal cell carcinoma (BCC) is the commonest periorbital tumour. Mohs' micrographic surgery and secondary reconstruction is the therapeutic gold standard for periorbital BCC. In cases of inoperability for any reason, therapeutic alternatives are needed. Since the approval of vismodegib, an orally administered, targeted BCC therapy is available. Nevertheless there is little information on the use of vismodegib for periorbital BCC.Patients and MethodsIn a retrospective study, we analysed the data of 4 patients treated with vismodegib since 2014. The patients' mean age before starting therapy was 87 years. The mean maximum tumour diameter was 22.0 mm.ResultsThe median follow-up was 17 months. The median treatment duration was 7.5 months. In 75 % of patients, complete clinical remission of BCC was achieved. In 25 % of patients, interim stabilisation of tumour growth was possible. The most common side effect of therapy was muscle spasm.ConclusionVismodegib is an effective treatment option for patients with periorbital BCC, in whom surgical treatment is not possible for any reason.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: M
authors.initials: M
authors.lastname: Keserü
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: S
authors.initials: S
authors.lastname: Green
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: S
authors.initials: S
authors.lastname: Dulz
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D009918:Orbital Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011725:Pyridines / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines